Actelion to announce results from 'proof-of-concept'/dose ranging study of its novel orexin receptor antagonist during the 2007 World Sleep Congress
ALLSCHWIL, Switzerland, Aug. 27, 2007 - Actelion will issue a media release on Sunday, 02 September 2007 (08:00 Basel CEST/ 16:00 Cairns, Australian EST), announcing the results from the proof-of-concept/dose ranging study into the effect of the novel orexin receptor antagonist in patients with primary insomnia. This announcement takes place at the start of the 2007 World Sleep Congress, Cairns, Australia to coincide with the publication of the congress abstract book
Pre-clinical data will be presented during the congress’ official poster sessions on Monday, 03 September 2007, 16:00-18:00 Cairns, Australian EST and Wednesday 05 September 2007, 16:00-18:00 Cairns, Australian EST.
Data from the proof-of-concept/dose ranging study will be presented as part of the late breaking oral presentation session on Wednesday 05 September 2007, 14:15-14:25 Cairns, Australian EST.
An Actelion-organized and hosted scientific educational event will take place in Cairns on Wednesday 05 September 2007 (13:00-14:00 Basel CEST/21:00-22:00 Cairns, Australian EST) and provide a forum for presentation and debate on the data presented at the congress. This meeting will also run as a live video webcast.
If you are attending the WSC and are interested in attending the educational event, please respond to Denise Hilpert on denise.hilpert@actelion.com. There will be room for 10-15 delegates at the event so acceptance will be based on a first-response basis.
For those of you wishing to dial-in via the internet or telephone, details are below.
Date/Time:
|
05 September 2007 |
13:00 – 14:00 |
Basel (CEST) |
|
|
21:00 – 22:00 |
Cairns (Australian EST) |
||
|
07:00 – 08:00 |
US (EDT) |
||
|
12:00 – 13:00 |
UK (BST) |
||
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before the Conference is due to start. Questions can be asked from phone participants after the audience discussion with CNS experts.
|
Dial: |
Europe: |
+ 41 44 580 6403 |
|
|
US: |
+ 1 866 895 8561 |
||
|
UK: |
+ 44 207 153 9962 |
||
Participant’s mode:
Listen only, then Q&A.
Webcast Access:
Webcast participants should visit the Actelion website http://www.actelion.com for further details 10-15 minutes before the conference is due to start. If you experience any access problems go directly to the URL. http://gaia.world-television.com/actelion/20070905/trunc
Participant’s mode:
Listen and watch only
Webcast Replay:
The archived Investor Webcast will be available for replay through http://www.actelion.com
approximately 60 minutes after the call has ended.
Posted: August 2007
